Home / Products /Genome Editing /KO Cell Lines /F3 Knockout cell line (HEK293)

F3 Knockout cell line (HEK293)

Catalog Number: KO17851

Price: Online Inquiry

Specifications Downloads Related products

Specifications

Product Information
Product Name F3 Knockout cell line (HEK293)
specification 1*10^6
Storage and transportation Dry ice preservation/T25 live cell transportation.
Cell morphology Epithelioid, adherent cell
Passage ratio 1:3~1:6
species Human
Gene F3
Gene ID 2152
Build method Electric rotation method / virus method
Mycoplasma testing Negative
Cultivation system 90%DMEM+10% FBS
Parental Cell Line HEK293
Quality Control Genotype: F3 Knockout cell line (HEK293) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins.
Gene Information
Gene Official Full Name coagulation factor III, tissue factorprovided by HGNC
Also known as TF; TFA; CD142
Gene Description This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces, for example, on monocytes. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli, and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Aug 2020]
Expression Ubiquitous expression in placenta (RPKM 54.0), gall bladder (RPKM 41.2) and 22 other tissues See more

Downloads

Please note that all services are for research use only. Not intended for any clinical use.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

0

There is no product in your cart.